Dendritic Cell Vaccine Using Cell-Penetrating Peptide Shows Promise Against Glioblastoma

Dendritic cells pulsed with CTP-fused tumor antigens (WT1 and BIRC5) showed enhanced expression of MHC molecules and co-stimulatory markers, indicating better antigen presentation. The vaccine also shifted immune signaling toward Th1 cytokine polarization, which favors anti-tumor immunity.

The CTP-fused antigen approach increased the number of IFN-gamma-producing effector T cells. These T cells showed enhanced killing of glioblastoma target cells expressing the matching antigens.

Combining the vaccine with PD-1 blockade further improved the cytotoxic T lymphocyte response, suggesting the two approaches work better together than either alone.

Glioblastoma is the deadliest brain cancer with a median survival of about 15 months. Current treatments rarely provide long-term control. A vaccine that effectively trains the immune system to recognize and kill glioblastoma cells could extend survival.

The CTP fusion approach solves a key problem in vaccine design by keeping the antigen in the cytoplasm where it can be processed and presented to killer T cells more effectively.

This was entirely an in vitro study. No animal models or patient data were included. Whether this approach would work against glioblastoma in a living brain, with its immune-suppressive environment, is unknown.

The study did not test whether CTP-fused antigens would work with naturally occurring, patient-derived dendritic cells.